Large personalised medicine trial in lung cancer heralds new research partnershipBMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g2837 (Published 17 April 2014) Cite this as: BMJ 2014;348:g2837
- Ingrid Torjesen
A large, ground breaking trial in which patients with non-small cell lung cancer will be given specific drugs according to the genetics of their tumour has been launched in the UK.
What makes this trial, called the National Lung Matrix trial, unique is that it is a collaboration between Cancer Research UK, the NHS and two drug companies—AstraZeneca and Pfizer. The trial will include drugs in development from both companies—12 from AstraZeneca and two from Pfizer—and patients will be enrolled into the trial arm offering the drug that best matches their genetic profile.
While other personalised or stratified medicine trials have been set up, these are mainly based at big cancer centres in the US. This UK trial will involve thousands of patients from across the UK. Biopsy …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial